Inhaled bronchodilators for cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 2, 2016, Pages

  Halfhide, Clare ^a   Evans, Hazel J ^b   Couriel, Jon ^a  

^a ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; IPRATROPIUM BROMIDE; SALBUTAMOL; SALMETEROL XINAFOATE;

CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; GENETIC DISORDER; HUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ADULT; ANALOGS AND DERIVATIVES; BRONCHIAL HYPERREACTIVITY; CHILD; COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; BRONCHIAL HYPERREACTIVITY; BRONCHODILATOR AGENTS; CHILD; CYSTIC FIBROSIS; HUMANS; IPRATROPIUM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALMETEROL XINAFOATE;

EID: 84969497970     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003428.pub3     Document Type: Review

References (77)

1. Avital A, Sanchez I, Chernick V. Efficacy of salbutamol and ipratropium bromide in decreasing bronchial hyperreactivity in children with cystic fibrosis. Pediatric Pulmonolgy 1992;13(1):34-7.
2. Dodd J, Barry S, Gallagher C. The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis [abstract]. American Journal of Respiratory and Critical Care Medicine 2001;163(5 Suppl):A88.
3. Dodd JD, Barry SC, Daly LE, Gallagher CG. Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis 2005;4(2):101-5.
4. Duncan FR, Penketh ARL, Hodson ME, Batten JC. The use of bronchodilators as an adjunct to physiotherapy in adults with cystic fibrosis [abstract]. 11th European Cystic Fibrosis Conference. 1982, issue 48.
5. Duncan FR, Penketh ARL, Hodson ME, Batten JC. The use of bronchodilators as an adjunct to physiotherapy in adults with cystic fibrosis [abstract]. Research Conference. 1982.
6. Eggleston PA, Rosentein BJ, Stackhouse CM, Mellitus ED, Baunmgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92.
7. Hordvik NL, Sammut PH, Judy CG, Strizek SJ, Colombo JL. The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 1996;154(1):156-60.
8. Hordvik NL, Judy CG, Sammut PH, Colombo JL. The effects of low and high dose salmeterol on the lung function of hospitalized patients with cystic fibrosis [abstract]. 11th Annual North American Cystic Fibrosis Conference. 1997.
9. Hordvik NL, Sammut PH, Judy CG, Colombo JL. Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis. Pediatric Pulmonolgy 1999;27(1):45-53.
10. Hordvik NL, Sammut PH, Judy CG, Colombo JL. A four week trial of high dose salmeterol vs. nebulized albuterol in patients with cystic fibrosis (CF) [abstract]. Pediatric Pulmonology 2000;30(Suppl 20):300.
11. Hordvik NL, Sammut PH, Judy CG, Colombo JL. Effectiveness and tolerability of high dose salmeterol in cystic fibrosis. Pediatric Pulmonolgy 2002;34(4):287-96.
12. Konig P, Poehler J, Barbero GJ. A placebo-controlled double-blind trial of the long-term effectsof albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology 1998;25(1):32-6.
13. Konig P, Poehler J, Barbero GJ. Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial [abstract]. Tenth Annual North American Cystic Fibrosis Conference. 1996.
14. Pitcher-Wilmott R, Matthew DJ, Ingram D, Tyson SL. Improvement in lung function after nebulised salbutamol and ipratropium in children with cystic fibrosis [abstract]. 11th European Cystic Fibrosis Conference. 1982:251.
15. Salvatore D, D'Andria M. Effects of salmeterol on arterial oxyhaemoglobin saturations in patients with cystic fibrosis. Pediatric Pulmonology 2002;34(1):11-5.
16. Sanchez I, Holbrow J, Chernick V. Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics 1992;120(3):486-8.
17. Sanchez I. Anticholinergenic therapy in cystic fibrosis patients. Archives de Pediatrie 1995;2:154S-8S.
18. Sanchez I, De Koster J, Holbrow J, Chernick V. The effect of high doses of inhaled salbutamol and ipratropium bromide in patients with stable cystic fibrosis. Chest 1993;104(3):842-6.
19. Serisier DJ, Coates AD, Bowler SD. Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest 2007;131(4):1181-7.
20. Serisier DJ, Coates AD, Bowler SD. Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis [abstract]. Respirology 2006;11(Suppl 2):A58.
21. Serisier DJ, Rice-McDonald G, Bowler SD, Coates AC. β-adrenergic agonists do not improve exercise capacity in cystic fibrosis [abstract]. Pediatric Pulmonology 2000;Suppl 20:305.
22. Sheehan DW, Goldstein A, Woodard S, McKoy K, Castile R. Factors influencing albuterol responsiveness in infants and young children with cystic fibrosis. Pediatric Pulmonology 2003;36(Suppl 25):323.
23. Turchetta A, Lucidi V, Bella S, Rosati P, Pastore E, Giordano U, et al. Is salmeterol effective in children with cystic fibrosis [abstract]. Israel Journal of Medical Sciences 1996;32(SUPPL):S191.
24. Turchetta A, Lucidi V, Calzolari A, Salerno T, Rosati P, Castro M. Effects of salmeterol on maximal oxygen consumption (VO2 max) in children with cystic fibrosis (CF) [abstract]. European Respiratory Journal 1998;12(Suppl 28):391s.
25. Wiebicke W, Poynter A, Montgomery M, Pagtakhan R. The effect of ipratropium bromide on lung function in patients with cystic fibrosis [Der Einfluß von Ipratropiumbromid auf die Lungenfunktion bei Patienten mit zystischer Fibrose]. Pneumologie 1990;44(Suppl 1):277-8.
26. Ziebach R, Petsch-Breitfeld B, Bichler M, Busch A, Riethmuller J, Stern M. Bronchodilatory effects of salbutamol, ipratropium bromide and their combination: Double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology 2001;31(6):431-5.
27. Avital A, SAnchez I, Holbrow J, Kryger M, Chernick V. Effect of theophlylline on lung function tests, sleep quality and night time SaO2 in children with cystic fibrosis.. American Review of Respiratory Disease 1991;144(6):1245-9.
28. Chua HL, Mel J, Le Souef PN. Prevention of ticarcillin-induced bronchoconstriction in cystic fibrosis by salbutamol pretreatment [abstract]. American Thoracic Society 1989 (American Review of Respiratory Disease Supplements) 1989;143:A294.
29. Chua HL, Walker SL, LeSouef PN, Sly PD. Comparison of efficacy of salbutamol and sodium cromoglycate in the prevention of ticarcillin-induced bronchoconstriction. Pediatric Pulmonology 1993;16(5):311-5.
30. Finnegan MJ, Hughes DV, Hodson ME. A randomised prospective double blind comparison of the use of intravenous or nebulised terbutaline in addition to standard treatment in the management of infective pulmonary exacerbations of cystic fibrosis [abstract]. 16th Annual Meeting of the European Working Group for Cystic Fibrosis. 1989:192.
31. Finnegan MJ, Hughes DV, Hodson ME. Comparison of nebulized and intravenous terbutaline during exacerbations of pulmonary infection in patients with cystic fibrosis. European Respiratory Journal 1992;5(9):1089-91.
32. Gulliver T, Wilson S, Williams G, Harris M, Cooper D. Nebulised tobramycin (intravenous solution) is tolerated without inducing cough and wheeze in cystic fibrosis patients (abstract). Proceedings of the Thoracic Society of Australia and New Zealand Annual Scientific Meeting. Adelaide, Australia, 2003:Abst #P139.
33. Kattan M, Mansell A, Levison H, Corey M, Krastins IR. Response to aerosol salbutamol, SCH 1000, and placebo in cystic fibrosis. Thorax 1980;35(7):531-5.
34. Kohler E, Sollich V, Schuster-Wonka R, Huhnerbein J, Jorch G. Does wearing a noseclip during inhalation improve lung deposition?. Journal of Aerosol Medicine 2004;17(2):116-22.
35. Konig P, Gayer D, Barbero GJ, Shaffer J. Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. Pediatric Pulmonology 1995;20(4):205-14.
36. Konig P, Goldstein D, Poehlmann M, Rife D, Ge B, Hewett J. Effect of nebulized albuterol on blood glucose in patients with diabetes mellitus with and without cystic fibrosis. Pediatric Pulmonology 2005;40(2):105-8.
37. Kovaleva LF, Guembitskaia TE, Gorbenko IA, Aleshin YuN. Combined systemic enzymotherapy and nebulizer therapy in the management of cystic fibrosis (CF) patients [abstract]. Proceedings of 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden. 2000:155.
38. Kraemer D, Liedtke C, Casaulta Aebischer C. Bronchodilator inhalation (BD) treatment in sequence with flutter VRP1 chest physiotherapy (CPT) in patients with cystic fibrosis [abstract]. Israel Journal of Medical Sciences 1996;32(SUPPL):S192.
39. Liedtke D, Casaulta Aebischer C, Martin N, Schibler A, Kraemer R. Mucociliar clearance (MCC) in patients with cystic fibrosis (CF) - Efficacy of beta2-inhalation therapy (beta2) in combination with respiratory physiotherapy [abstract]. Schweizerische Medizinische 1996;126(Suppl 78):29S.
40. Larsen GL, Barron RJ, Cotton EK, Brooks JG. A comparative study of atropine sulfate and isoproterenol hydrochloride in cystic fibrosis [abstract]. American Review of Respiratory Disease 1978;117:298.
41. Larsen GL, Barron RJ, Cotton EK, Brooks JG. A comparative study of inhaled atropine and isoproterenol hydrochloride in cystic fibrosis. American Review of Respiratory Disease 1979;119(3):399-407.
42. Liedtke D, Aebischer C, Martin N, Schiber A, Kraemer R. Mucociliary clearance in patients with cystic fibrosis(CF) - Efficacy of beta2-inhalation therapy (beta2) in combination with respiratory physiotherapy [abstract]. Schweizerische Medizinische Wochenschrift 1996;126(Suppl 78):29s.
43. Maayan C, Bar Yishay E, Yaacobi T, Marcus Y, Katznelson D, Yahav Y, et al. Immediate effect of various treatments on lung function in infants with cystic fibrosis. Respiration 1989;55(3):144-51.
44. Marks JH, Fooy C, Anderson K, Homnick DN. Nebulized albuterol delivered with positive expiratory pressure (PEP) and the flutter device in patients with cystic fibrosis: an assessment of bronchodilator response compared to standard nebulizer therapy [abstract]. American Journal of Respiratory and Critical Care Medicine 1998;157(3 Suppl):A130.
45. Mortensen J, Hansen A, Falk M, Groth S, Kirketerp I. Lung mucociliary clearance in cystic fibrosis after inhalation of a beta-2-agonist [abstract]. 17th European Cystic Fibrosis Conference. 1991:119.
46. Mortensen J, Hansen A, Falk M, Nielsen IK, Groth S. Reduced effect of inhaled beta 2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis. Chest 1993;103(3):805.
47. Nikolaizik WH, Jenni-Galovic V, Schoni MH. Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis. European Journal of Pediatrics 1996;155(7):608-11.
48. Orlik T, Sands D, Kluba L. The influence of bronchodilators on chest physiotherapy effect in children with CF [abstract]. 12th European Respiratory Society Annual Congress; 2002, Sept 14-18; Stockholm. 2002.
49. Orlik T, Sands D, Kluba L. The influence of bronchodilators on chest physiotherapy effect in children with CF [abstract]. Journal of Cystic Fibrosis 2002;1(Suppl 1):S180.
50. Peckham DG, Conn A, Chotai C, Lewis S, Knox AJ. Effect of oral digoxin, topical ouabain and salbutamol on transepithelial nasal potential difference in patients with cystic fibrosis. Clinical Science 1995;89(3):277-84.
51. Robuschi M, Spagnotto S, Amoretti M, Gambaro G, Giunta MG, Vaghi A, et al. Refractoriness to ultrasonically nebulized water (H2O) in cystic fibrosis [abstract]. European Respiratory Journal 1990;3(Suppl 10):74s.
52. Shapiro GG, Bamman J, Kanarek P, Bierman CW. The paradoxical effect of adrenergic and methylxanthine drugs in cystic fibrosis. Pediatrics 1976;58(5):740-3.
53. Newth CJL, Arce P, Nickerson BG, Eigen H. The efficacy of cromolyn sodium versus placebo in cystic fibrosis [abstract]. American Thoracic Society 1988 (American Review of Respiratory Disease Supplements) 1988;137:303.
54. Sivan Y, Arce P, Eigen H, Nickerson BG, Newth CJ. A double-blind randomized study of sodium cromoglycate versus placebo in patients with cystic fibrosis and bronchial hyperreactivity. Journal of Allergy and Clinical Immunology 1990;85(3):649-54.
55. Holsclaw DS, Tecklin JS. The effectiveness of bronchial drainage and aerosol inhalation in cystic fibrosis. Cystic Fibrosis 1977:230-8.
56. Tecklin JS, Holsclaw DS Jr. Bronchial drainage with aerosol medications in cystic fibrosis. Physical Therapy 1976;56(9):999-1003.
57. Van Asperen PP, Manglick P, Allen H. Mechanisms of bronchial hyperreactivity in cystic fibrosis. Pediatric Pulmonology 1988;5(3):139-44.
58. Weintraub SJ, Eschenbacher WL. The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest 1989;95(4):861-4.
59. Bessaci K//Milliot M//Zahm J//Vilprey M//Coraux C//Mauran P//Vitry F//Gauthier F//Birembaut P//Abely M. Effects of inhaled association of salmeterol-fluticasone propionate on lung and epithelial cell functions in cystic fibrosis children [abstract]. Pediatric Pulmonology 2008:384.
60. Bessaci K//Milliot M//Zahm JM//Coraux C//Mauran P//Vitry F//Gauthier F//Abely M. Effects of inhaled salmeterol-fluticasone propionate on lung and epithelial cell functions in cystic fibrosis children: a double blind crossover study [abstract]. Journal of Cystic Fibrosis 2008, issue Suppl 2:S66.
61. NCT00737100 . Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00737100 (accessed 21 September 2010).
62. NCT01179347 . Tiotropium Bromide in Cystic Fibrosis. clinicaltrialsfeeds.org/clinical-trials/show/NCT01179347 (accessed 21 September 2010).
63. ATS/ERS Task Force. Standardisation of lung function testing. European Respiratory Journal 2005;26(2):319-38.
64. Balffour-Lynn I M, Elbourn J S. "CF Asthma": what is it and what do we do about it?. Thorax 2002;57:742-748.
65. Brand P. Bronchodilators in cystic fibrosis. Journal of the Royal Society of Medicine 2000;93(Suppl 38):37-9.
66. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Thorax 2008;63(Supplement 4):iv1-iv121. [DOI: ]
67. CF Foundation. National Patient Registry. Annual Data Report [Bethesda, Maryland] 2000.
68. Cropp GJ. Effectiveness of bronchodilators in cystic fibrosis. American Journal of Medicine 1996;100(1A):19-29S.
69. Dowling RB, Johnson M, Cole PJ, Wilson R. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. European Respiratory Journal 1998;11(1):86-90.
70. Dowling RB, Johnson M, Cole PJ, Wilson R. Effects of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory tract in vitro. European Respiratory Journal 1999;14(2):363-9.
71. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analysis involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
72. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
73. Holzer FJ, Olinsky A, Phelan PD. Variability of airways hyper-reactivity and allergy in cystic fibrosis. Archives of Disease in Childhood 1981;56(6):455-9.
74. Konig P, Rejent N. Subjective and objective means of assessing cystic fibrosis and asthma. Annals of Allergy 1982;49(2):86-92.
75. Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR. Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and coordinators of the epidemiological study of cystic fibrosis. Pediatric Pulmonology 1999;28(4):248-54.
76. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment in controlled trials. JAMA 1995;273:408-12.
77. Zach MS, Oberwaldner B, Forche G, Polgar G. Bronchodilators increase airway instability in cystic fibrosis. American Review of Respiratory Disease 1985;131(4):527-43.